Kauffman Michael Form 4 April 10, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to STATEMENT OF CHANGE

Number: 3235-0287

Sypirac: January 31,

if no longer subject to Section 16. Form 4 or Expires: 2005
Estimated average

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

burden hours per response... 0.5

Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

See Instruction 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

(Print or Type Re	esponses)						
1. Name and Address of Reporting Person * Kauffman Michael			2. Issuer Name and Ticker or Trading Symbol Karyopharm Therapeutics Inc. [KPTI]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O KARYO THERAPEU' AVENUE		(Middle) 85 WELLS	3. Date of Earliest Transaction (Month/Day/Year) 04/09/2018	_X_ Director 10% Owner X Officer (give title Other (specify below) Chief Executive Officer			
NEWTON, M	(Street) 1A 02459		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Ac	equired, Disposed of, or Beneficially Owned			

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)		ed of (`	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	04/09/2018		M(1)	10,000	A	\$ 0.264	723,510	I	By Spouse		
Common Stock	04/09/2018		S <u>(1)</u>	10,000	D	\$ 12.4829 (2)	713,510	I	By Spouse		
Common Stock							512,143	D			
Common Stock							47,309	I	By GRAT (3)		

Common Stock 47,309 I Spouse's $\frac{1}{6RAT^{(4)}}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.264	04/09/2018		M <u>(1)</u>	10,000	<u>(5)</u>	12/15/2021	Common Stock	10,000

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Kauffman Michael

NEWTON, MA 02459

C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE

X

Chief Executive Officer

Signatures

/s/ Christopher B. Primiano, Attorney-in-Fact for Michael G. Kauffman

04/10/2018

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

Reporting Owners 2

Edgar Filing: Kauffman Michael - Form 4

- Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$12.20 to \$12.64,
- (2) inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (3) These shares are held by the Michael G. Kauffman 2016 Qualified Annuity Interest Trust.
- (4) These shares are held by the Sharon Shacham 2016 Qualified Annuity Interest Trust.
- (5) This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 14, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.